.Nature Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of people along with HER2+ state-of-the-art breast cancer cells and also energetic or even secure mind metastases revealed consistent intracranial activity and also systemic efficacy of T-DXd.